These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 1186499)

  • 1. The role of glucagon in the pathogenesis of the endogenous hyperglycemia of diabetes mellitus.
    Sakurai H; Dobbs RE; Unger RH
    Metabolism; 1975 Nov; 24(11):1287-97. PubMed ID: 1186499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs.
    Sakurai H; Dobbs R; Unger RH
    J Clin Invest; 1974 Dec; 54(6):1395-402. PubMed ID: 4436439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapancreatic glucagon in control of glucose turnover in depancreatized dogs.
    Ross G; Lickley L; Vranic M
    Am J Physiol; 1978 Feb; 234(2):E213-19. PubMed ID: 623297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State of metabolic control determines role of epinephrine-glucagon interaction in glucoregulation in diabetes.
    Kemmer FW; Lickley HL; Gray DE; Perez G; Vranic M
    Am J Physiol; 1982 Jun; 242(6):E428-36. PubMed ID: 6124126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin.
    Sherwin RS; Hendler R; DeFronzo R; Wahren J; Felic P
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):348-52. PubMed ID: 264686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon suppression improves glucoregulation in moderate but not chronic severe diabetes.
    Lickley HL; Kemmer FW; Doi K; Vranic M
    Am J Physiol; 1983 Oct; 245(4):E424-9. PubMed ID: 6137957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of somatostatin to decrease blood glucose by suppression of extrapancreatic glucagon in severely diabetic depancreatized dogs.
    Matsuyama T; Tanaka R; Shima K; Tarui S
    Endocrinol Jpn; 1978 Dec; 25(6):529-32. PubMed ID: 751798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catecholamine responses and their interactions with other glucoregulatory hormones.
    Vranic M; Gauthier C; Bilinski D; Wasserman D; El Tayeb K; Hetenyi G; Lickley HL
    Am J Physiol; 1984 Aug; 247(2 Pt 1):E145-56. PubMed ID: 6147092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of glucagon in the control of futile cycling as studied in alloxan-diabetic dogs.
    Lickley HL; Kemmer FW; el-Tayeb KM; Vranic M
    Diabetologia; 1987 Mar; 30(3):175-82. PubMed ID: 2884159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of glucagon in mediating epinephrine-induced hyperglycemia in alloxan-diabetic dogs.
    Perez G; Kemmer FW; Lickley HL; Vranic M
    Am J Physiol; 1981 Oct; 241(4):E328-35. PubMed ID: 7032319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon: role in the hyperglycemia of diabetes mellitus.
    Dobbs R; Sakurai H; Sasaki H; Faloona G; Valverde I; Baetens D; Orci L; Unger R
    Science; 1975 Feb; 187(4176):544-7. PubMed ID: 1089999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
    Sandhu H; Wiesenthal SR; MacDonald PE; McCall RH; Tchipashvili V; Rashid S; Satkunarajah M; Irwin DM; Shi ZQ; Brubaker PL; Wheeler MB; Vranic M; Efendic S; Giacca A
    Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogs.
    Valverde I; Dobbs R; Unger RH
    Metabolism; 1975 Sep; 24(9):1021-8. PubMed ID: 1152674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The essential role of glucagon in the pathogenesis of diabetes mellitus.
    Unger RH; Orci L
    Lancet; 1975 Jan; 1(7897):14-6. PubMed ID: 46337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of experimental insulin deficiency on glucagon secretion.
    Müller WA; Faloona GR; Unger RH
    J Clin Invest; 1971 Sep; 50(9):1992-9. PubMed ID: 4935445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration.
    Starke A; Imamura T; Unger RH
    J Clin Invest; 1987 Jan; 79(1):20-4. PubMed ID: 2878938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the mechanism of diazoxide-induced hyperglycemia.
    Altszuler N; Moraru E; Hampshire J
    Diabetes; 1977 Oct; 26(10):931-5. PubMed ID: 908462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia.
    Rizza RA; Cryer PE; Gerich JE
    J Clin Invest; 1979 Jul; 64(1):62-71. PubMed ID: 36413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia.
    Klaff LJ; Taborsky GJ
    Diabetes; 1987 May; 36(5):592-6. PubMed ID: 2883057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.
    Gerich JE; Lorenzi M; Bier DM; Tsalikian E; Schneider V; Karam JH; Forsham PH
    J Clin Invest; 1976 Apr; 57(4):875-84. PubMed ID: 820717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.